PRTC vs. GNS, ERGO, SLN, OXB, HZD, FARN, VRP, AVCT, ARIX, and CIR
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Genus (GNS), Ergomed (ERGO), Silence Therapeutics (SLN), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Avacta Group (AVCT), Arix Bioscience (ARIX), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry.
PureTech Health vs. Its Competitors
Genus (LON:GNS) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.
Genus has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.
77.8% of Genus shares are owned by institutional investors. Comparatively, 79.9% of PureTech Health shares are owned by institutional investors. 0.8% of Genus shares are owned by insiders. Comparatively, 15.9% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Genus has a net margin of 1.18% compared to PureTech Health's net margin of -17,620.94%. Genus' return on equity of 1.41% beat PureTech Health's return on equity.
In the previous week, Genus and Genus both had 1 articles in the media. Genus' average media sentiment score of 0.29 beat PureTech Health's score of 0.00 indicating that Genus is being referred to more favorably in the media.
Genus currently has a consensus price target of GBX 2,650, indicating a potential upside of 6.85%. PureTech Health has a consensus price target of GBX 455, indicating a potential upside of 245.22%. Given PureTech Health's higher probable upside, analysts clearly believe PureTech Health is more favorable than Genus.
Genus has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.
Summary
Genus beats PureTech Health on 9 of the 14 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
This page (LON:PRTC) was last updated on 8/8/2025 by MarketBeat.com Staff
Free PRTC Stock Alerts